Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Short Interest Update

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) saw a significant decline in short interest in July. As of July 31st, there was short interest totalling 4,820,000 shares, a decline of 9.9% from the July 15th total of 5,350,000 shares. Approximately 4.7% of the shares of the stock are short sold. Based on an average trading volume of 1,100,000 shares, the short-interest ratio is currently 4.4 days.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on CPRX shares. Citigroup raised their price target on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a research report on Friday, August 9th. HC Wainwright boosted their target price on Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Oppenheimer reaffirmed an “outperform” rating and issued a $29.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, June 6th. Truist Financial boosted their price objective on shares of Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Finally, StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 9th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $29.50.

Catalyst Pharmaceuticals Stock Up 0.6 %

Shares of Catalyst Pharmaceuticals stock traded up $0.12 on Monday, hitting $19.99. The stock had a trading volume of 1,136,365 shares, compared to its average volume of 1,293,560. Catalyst Pharmaceuticals has a one year low of $11.55 and a one year high of $20.31. The stock’s 50-day simple moving average is $16.50 and its two-hundred day simple moving average is $15.78. The stock has a market cap of $2.36 billion, a price-to-earnings ratio of 36.80 and a beta of 0.70.

Insider Activity at Catalyst Pharmaceuticals

In other news, CEO Richard J. Daly sold 17,323 shares of the company’s stock in a transaction on Tuesday, June 4th. The shares were sold at an average price of $15.97, for a total value of $276,648.31. Following the transaction, the chief executive officer now owns 234,824 shares of the company’s stock, valued at $3,750,139.28. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, CEO Richard J. Daly sold 17,323 shares of the company’s stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $15.97, for a total value of $276,648.31. Following the transaction, the chief executive officer now directly owns 234,824 shares in the company, valued at $3,750,139.28. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Carmen Jeffrey Del sold 7,541 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Friday, June 7th. The shares were sold at an average price of $16.07, for a total transaction of $121,183.87. Following the sale, the insider now owns 18,427 shares of the company’s stock, valued at $296,121.89. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 146,255 shares of company stock valued at $2,441,748. Corporate insiders own 11.00% of the company’s stock.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in CPRX. Raymond James & Associates boosted its holdings in shares of Catalyst Pharmaceuticals by 4.2% during the fourth quarter. Raymond James & Associates now owns 50,279 shares of the biopharmaceutical company’s stock worth $845,000 after purchasing an additional 2,045 shares during the period. Nisa Investment Advisors LLC lifted its stake in Catalyst Pharmaceuticals by 306.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 5,079 shares of the biopharmaceutical company’s stock worth $85,000 after acquiring an additional 3,829 shares during the period. Cerity Partners LLC lifted its stake in Catalyst Pharmaceuticals by 11.5% in the fourth quarter. Cerity Partners LLC now owns 17,231 shares of the biopharmaceutical company’s stock worth $290,000 after acquiring an additional 1,780 shares during the period. Louisiana State Employees Retirement System bought a new position in Catalyst Pharmaceuticals in the 4th quarter worth $842,000. Finally, Parkside Financial Bank & Trust bought a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter valued at about $31,000. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.